ETRA · Electra Therapeutics, Inc. · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-09-18 |
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the pricing of its upsized |
| 2026-09-10 |
Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases
Second clinical-stage asset generated from the company’s proprietary library of SIRP-targeted antibodies SOUTH SAN FRANCISCO, CA, Sept. 10, 2026 – Electra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of |
| 2026-09-09 |
Electra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer
SOUTH SAN FRANCISCO, CA, Sept. 9, 2026 – Electra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the promotion of Chris Clark, CFA, to Chief Financial Officer. |
| 2026-05-05 |
Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
SOUTH SAN FRANCISCO, CA, May 5, 2026 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced dosing of the first patient in a Phase 1 study of ipsoprubart (ELA026) in patients with T cell |
| 2026-01-05 |
Electra Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, CA, January 5, 2026 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that it will present at the 44th annual J.P. Morgan Healthcare Conference, taking place January |
| 2025-12-02 |
Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting
SOUTH SAN FRANCISCO, CA, December 2, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced it will present two posters on the ELA026 clinical program in secondary hemophagocytic |
| 2025-10-22 |
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication expansion of ELA026 in hematologic cancers and advance second pipeline program, ELA822, into the |
| 2025-10-22 |
Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need Electra has initiated the SURPASS global pivotal trial evaluating ELA026 in patients with sHLH SOUTH SAN FRANCISCO, CA, |
| 2025-10-22 |
Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
The SURPASS study is enrolling patients at research sites across the U.S. and Europe ELA026 targets signal regulatory proteins (SIRP) as a novel approach to treating the life-threatening hyperinflammatory pathology of sHLH SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a |
| 2025-08-04 |
Electra Therapeutics Announces ELA026 Granted EMA Orphan Drug Designation for the Treatment of Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
ELA026 has demonstrated promising potential to address the high unmet need for patients with sHLH, a rare, life-threatening hyperinflammatory disease with limited treatment options SOUTH SAN FRANCISCO, CA, August 4, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-01-13 | 44th annual J.P. Morgan Healthcare Conference | Conference |